A Phase 2 interventional study of K-645 100 mg and K-645 10 mg in Migraine, sponsored by TriGemX Bio, Inc.. Terminated at 18 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by TriGemX Bio, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 697 studies in Migraine Disorders with a site in United States — 92 open to participants now, 114 under way, 27 of them phase 3. Migraine Disorders · United States.
Among the 697 studies in Migraine Disorders with a site in United States, this one is the 240th largest by enrollment of the 610 interventional ones that give a count, is one of 32 that started in 2025, is one of 90 in phase 2, and was the 653rd registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →92 of the 697 studies in Migraine Disorders with a site in United States are open now. Recruiting first, the newest first:
Salvia BioElectronics · Sites in United States
Ages 22–84
University of Colorado, Denver · Sites in United States
Ages 12–17
Columbia University · Sites in United States
Ages 18–55
TriGemX Bio, Inc. · Sites in United States
Ages 18–75
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
697 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 113 · Phase 3 151 · Phase 4 101
First in 1999; this study’s year is marked. 32 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 78 across the 610 interventional studies, 195 across the 84 observational. Of the 528 that completed or were terminated, 305 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
345 of 697 have an industry lead sponsor. The 10 most frequent:
TriGemX Bio, Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
TriGemX Bio, Inc. has 5 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
47 of the studies in Migraine Disorders with a site in United States that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07645924Phase 3TriGemX Bio, Inc.A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | 2027-02 |
| NCT05598723Phase 3Naval Medical Center Camp LejeuneBOTOX® vs. XEOMIN® for Chronic Migraine | 2027-02-24 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
Add all 47 to your calendar (.ics) → With an account.
Among the 697 studies in Migraine Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine.
The criteria were revised on the registry on Nov 5, 2026. See what changed
INCLUSION CRITERIA:
Meet the following requirements:
Is a male who agrees to all of the following:
Note: Contraception/condom requirements are waived if partner is NOT of childbearing potential (i.e. is male or is a female who is or surgically sterile [post-hysterectomy or bilateral salpingectomy]).
OR
Is a female who is of non-childbearing potential defined by at least 1 of the following criteria:
OR c. Is a female of and:
AND
agrees to use (or have their partner use) a birth control method that is highly effective**. Acceptable methods of birth control are:
Vasectomized partner * Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.
KEY EXCLUSION CRITERIA:
Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study. Note: Female participants of childbearing potential must have a negative serum pregnancy test (beta-human chorionic gonadotropin [beta-hCG]) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.
Migraine history-related exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In treatment sequence 1, participants were randomized to receive single oral doses of K-645 100 mg, matching placebo, and then K-645 10 mg during Periods1, 2, and 3, respectively.
Drug: K-645 100 mg · Drug: K-645 10 mg · Drug: Placebo
In treatment sequence 2, participants were randomized to receive single oral doses of matching placebo, K-645 100 mg, and then K-645 10 mg during Periods 1, 2, and 3, respectively.
Drug: K-645 100 mg · Drug: K-645 10 mg · Drug: Placebo
Single oral dose of K-645 100 mg
Single oral dose of K-645 10 mg
Single oral dose of matching placebo
Pain Freedom
Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)
Time frame: 2 hours post-dose
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia, or Photophobia)
Assessed using the number of evaluable participants that reported the absence of their MBS. The MBS was measured using a binary scale (0 = absent, 1 = present)
Time frame: 2 hours post-dose
Pain Relief
Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).
Time frame: 2 hours post-dose
Percentage of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
Time frame: Up to 7 days after the last dose of study medication
Percentage of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)
Serious adverse events were assessed in the Safety Analysis Set.
Time frame: Up to 7 days after the last dose of study medication
| Milestone | K-645 100 mg - Placebo - K-645 10 mg | Placebo - K-645 100 mg - K-645 10 mg |
|---|---|---|
| Started | 67 | 67 |
| Completed | 18 | 23 |
| Not completed | 49 | 44 |
Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)
| Participants | Placebo | K-645 100 mg | K-645 10 mg |
|---|---|---|---|
| Pain Freedom | 12 | 5 | 3 |
Assessed using the number of evaluable participants that reported the absence of their MBS. The MBS was measured using a binary scale (0 = absent, 1 = present)
| Participants | Placebo | K-645 100 mg | K-645 10 mg |
|---|---|---|---|
| Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia, or Photophobia) | 17 | 17 | 10 |
Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).
| Participants | Placebo | K-645 100 mg | K-645 10 mg |
|---|---|---|---|
| Pain Relief | 39 | 30 | 15 |
| Participants | Placebo | K-645 100 mg | K-645 10 mg |
|---|---|---|---|
| Percentage of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs) | 3 | 4 | 2 |
Serious adverse events were assessed in the Safety Analysis Set.
| Participants | Placebo | K645 100 mg | K645 10 mg |
|---|---|---|---|
| Percentage of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs) | 0 | 0 | 0 |
Collected over Up to 7 days after administration of study medication. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/104 (0%) | 0/104 (0%) | 3/104 (2.9%) |
| K-645 100 mg | 0/108 (0%) | 0/108 (0%) | 4/108 (3.7%) |
| K-645 10 mg | 0/41 (0%) | 0/41 (0%) | 2/41 (4.9%) |
| Event | Placebo | K-645 100 mg | K-645 10 mg |
|---|---|---|---|
| Temporomandibular pain and dysfunction syndromeMusculoskeletal and connective tissue disorders | 0/104 | 1/108 | 1/41 |
| Thermal burnInjury, poisoning and procedural complications | 0/104 | 0/108 | 1/41 |
| Back painMusculoskeletal and connective tissue disorders | 1/104 | 0/108 | 0/41 |
| Vision blurredEye disorders | 1/104 | 0/108 | 0/41 |
| Tooth abscessInfections and infestations | 1/104 | 0/108 | 0/41 |
| Neck painMusculoskeletal and connective tissue disorders | 0/104 | 1/108 | 0/41 |
| NauseaGastrointestinal disorders | 0/104 | 1/108 | 0/41 |
| SomnolenceNervous system disorders | 0/104 | 1/108 | 0/41 |
The baseline analysis population included all participants who were in the modified Intent-to-Treat (mITT) analysis set for the primary endpoint for at least one study medication. For each study medication, the mITT set for the primary endpoint comprised all randomized participants who took that study medication to treat a qualifying migraine of moderate/severe baseline pain intensity (Grade 2 or 3, on a 4-point numeric rating) and provided a pain rating at baseline and at 2 hours post-dose.
| Age, Continuous(years) | K-645 100 mg - Placebo - K-645 10 mg | Placebo - K-645 100 mg - K-645 10 mg | Total |
|---|---|---|---|
| Mean | 44.1 ± 11.37 | 45.2 ± 11.33 | 44.7 ± 11.31 |
| Age, Customized(Participants) | K-645 100 mg - Placebo - K-645 10 mg | Placebo - K-645 100 mg - K-645 10 mg | Total |
|---|---|---|---|
| <65 years | 58 | 62 | 120 |
| ≥65 years | 1 | 2 | 3 |
| Sex: Female, Male(Participants) | K-645 100 mg - Placebo - K-645 10 mg | Placebo - K-645 100 mg - K-645 10 mg | Total |
|---|---|---|---|
| Female | 53 | 55 | 108 |
| Male | 6 | 9 | 15 |
| Ethnicity (NIH/OMB)(Participants) | K-645 100 mg - Placebo - K-645 10 mg | Placebo - K-645 100 mg - K-645 10 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 9 | 16 |
| Not Hispanic or Latino | 51 | 53 | 104 |
| Unknown or Not Reported | 1 | 2 | 3 |
| Race/Ethnicity, Customized(Participants) | K-645 100 mg - Placebo - K-645 10 mg | Placebo - K-645 100 mg - K-645 10 mg | Total |
|---|---|---|---|
| American Indian or Alaskan Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Black or African American | 7 | 14 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 49 | 46 | 95 |
| Other | 0 | 1 | 1 |
| Multiple | 2 | 1 | 3 |
| Not Reported/Unknown | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2025 to primary completion in Nov 2025, 3 months.
Results were first posted in Nov 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TriGemX Bio, Inc.